Clinical outcome of patients with FIGO stage IA2 squamous cell carcinoma of the uterine cervix.

Abstract:

OBJECTIVE:The objective of this analysis was to present the clinical outcome of the patients with FIGO stage IA2 squamous cell cervical cancer treated at the Department of Obstetrics and Gynecology between 1973 and 2009, and to clarify the discrepancies in clinical guidelines regarding the radicality of treatment applied in patients with stage IA2 squamous cell cervical cancer. METHODS:In our study we enrolled 89 women, diagnosed with FIGO stage IA2 squamous cell microinvasive carcinoma (MIC) in the period 1973-2009. The analysis involved the following parameters women's age at operation, type of operation, cell type, mitotic activity, invasive growth pattern, host defense reaction, lymph-vascular space invasion and patient's survival. Additionally, using the Rainer's scoring system, the prognostic score for each MIC was calculated. RESULTS:The mean women's age at operation was 41.48 ± 10.67 years. The mean depth of invasion was 3.09 ± 1.13 mm, and the mean area of carcinoma 4.05 ± 2.40 mm(2). In 66 (74.2%) women the suggested treatment was conization, according to the Rainer's scoring system and individualization of treatment based on decision of the tumor board. Three of the 89 patients diagnosed with MIC stage IA2 died; only in one patient the cause of death was cervical carcinoma. At the end of the observed period the survival rate was 98.0%. CONCLUSION:We may conclude that conservative management of stage IA2 MIC is safe when exact evaluation of tumor extension and surgical margins of the cone are considered, and results in very low risk of recurrence, lymph node disease, and death caused by cancer. We believe that our experience will contribute to the achievement of the international consensus concerning the treatment of IA2 MIC.

journal_name

Gynecol Oncol

journal_title

Gynecologic oncology

authors

Smrkolj S,Pogačnik RK,Slabe N,Rakar S

doi

10.1016/j.ygyno.2011.09.032

subject

Has Abstract

pub_date

2012-01-01 00:00:00

pages

68-71

issue

1

eissn

0090-8258

issn

1095-6859

pii

S0090-8258(11)00802-X

journal_volume

124

pub_type

杂志文章
  • Cadherins, catenins and cell cycle regulators: impact on survival in a Gynecologic Oncology Group phase II endometrial cancer trial.

    abstract:OBJECTIVE:We evaluated the clinical relevance of catenins, cadherins and cell cycle regulators in stage IV or recurrent endometrial carcinoma in a multi-center phase II trial (GOG protocol #119). METHODS:Tissue microarrays of metastatic or recurrent (n=42) tumor were developed and immunohistochemistry was performed. A...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.ygyno.2011.07.005

    authors: Singh M,Darcy KM,Brady WE,Clubwala R,Weber Z,Rittenbach JV,Akalin A,Whitney CW,Zaino R,Ramirez NC,Leslie KK

    更新日期:2011-11-01 00:00:00

  • Detection of disseminated tumor cells in patients with gynecological cancers.

    abstract:OBJECTIVES:The presence of disseminated tumor cells (DTC) in breast cancer patients is associated with poor prognosis. However, there are limited data about the prevalence and prognostic impact of DTC in patients with gynecological tumors. The aim of this study was to evaluate the presence of DTC in the bone marrow (BM...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2006.05.049

    authors: Fehm T,Becker S,Bachmann C,Beck V,Gebauer G,Banys M,Wallwiener D,Solomayer EF

    更新日期:2006-12-01 00:00:00

  • Primary surgical therapy of ovarian cancer: how much and when.

    abstract::From July 1975 through December 1985, 328 patients with ovarian malignancies were treated. Of these, 302 had epithelial invasive malignancies and constitute the study group. The impact of the operative procedure, findings, and subsequent treatment is evaluated. Patients who underwent extensive debulking procedures suc...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(90)90277-r

    authors: Potter ME,Partridge EE,Hatch KD,Soong SJ,Austin JM,Shingleton HM

    更新日期:1991-03-01 00:00:00

  • Reconstructive surgery following resection of primary vulvar cancers.

    abstract:OBJECTIVE:This study describes the surgical treatment and follow-up of 213 patients with primary vulvar cancer; particular attention is given to reconstructive surgical procedures. METHODS:The clinical and pathological parameters of the patients were recorded according to standardized procedures, and the data concerni...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2005.05.031

    authors: Weikel W,Hofmann M,Steiner E,Knapstein PG,Koelbl H

    更新日期:2005-10-01 00:00:00

  • Effective chemotherapy consisting of bleomycin, vincristine, mitomycin C, and cisplatin (BOMP) for a patient with inoperable vulvar cancer.

    abstract::Combination chemotherapy consisting of bleomycin, vincristine, mitomycin C, and cisplatin (BOMP) was first applied to an inoperable case (57-year-old) with FIGO stage IV (T3N3 + M1B) squamous cell carcinoma of the vulva. After three courses of BOMP therapy, the patient achieved a complete response with few toxic effec...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(90)90156-f

    authors: Shimizu Y,Hasumi K,Masubuchi K

    更新日期:1990-03-01 00:00:00

  • Pre-chemotherapy hemoglobin levels and survival in patients with advanced epithelial ovarian cancer who received a first-line taxane/platinum-based regimen: results of a multicenter retrospective Italian study.

    abstract:OBJECTIVE:The aim of this retrospective multicenter study was to assess whether the pre-chemotherapy hemoglobin levels have any impact on the clinical outcome of patients with advanced epithelial ovarian cancer who received a first-line taxane/platinum-based regimen. METHODS:The study was conducted on 315 patients who...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.ygyno.2005.04.012

    authors: Gadducci A,Sartori E,Landoni F,Zola P,Maggino T,Colombo N,Fanucchi A,Chiudinelli F,Lapresa M,Maria Ferrero A

    更新日期:2005-07-01 00:00:00

  • Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer.

    abstract:OBJECTIVE:Potential predictive/prognostic angiogenic markers were prospectively examined in a phase II trial of bevacizumab in epithelial ovarian cancer (EOC)/primary peritoneal cancer (PPC). METHODS:Recurrent/persistent EOC/PPC patients were treated with bevacizumab (15 mg/kg IV q21days) until disease progression. Va...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.ygyno.2010.08.016

    authors: Han ES,Burger RA,Darcy KM,Sill MW,Randall LM,Chase D,Parmakhtiar B,Monk BJ,Greer BE,Connelly P,Degeest K,Fruehauf JP

    更新日期:2010-12-01 00:00:00

  • Intraperitoneal alpha-interferon alternating with cisplatin in residual ovarian carcinoma: a phase II Gynecologic Oncology Group study.

    abstract:OBJECTIVE:The aim of this study was to study the combination of intraperitoneal alpha-interferon and cisplatin administered second-line in an alternating sequence in small volume residual epithelial ovarian cancer after second-look surgery and the activity of this combination based on prior response to first-line plati...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1006/gyno.1999.5455

    authors: Berek JS,Markman M,Blessing JA,Kucera PR,Nelson BE,Anderson B,Hanjani P

    更新日期:1999-07-01 00:00:00

  • Dose-volume effects in pathologic lymph nodes in locally advanced cervical cancer.

    abstract:OBJECTIVE:In cervical cancer patients, dose-volume relationships have been demonstrated for tumor and organs-at-risk, but not for pathologic nodes. The nodal control probability (NCP) according to dose/volume parameters was investigated. MATERIAL AND METHODS:Patients with node-positive cervical cancer treated curative...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2017.12.028

    authors: Bacorro W,Dumas I,Escande A,Gouy S,Bentivegna E,Morice P,Haie-Meder C,Chargari C

    更新日期:2018-03-01 00:00:00

  • An analysis of approaches to the management of endometrial cancer in North America: a CTF study.

    abstract:OBJECTIVE:The aim of this study was to define the clinical-therapeutical approach to endometrial cancer now being followed in some of the most important centers of reference for gynecological cancer in North America by means of a questionnaire. STUDY DESIGN:The questionnaire focused on four principal areas: (1) surgic...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1006/gyno.1998.4951

    authors: Maggino T,Romagnolo C,Landoni F,Sartori E,Zola P,Gadducci A

    更新日期:1998-03-01 00:00:00

  • Quality of life in cervical cancer survivors: patient and provider perspectives on common complications of cervical cancer and treatment.

    abstract:OBJECTIVE:This study's objective was to quantify the impact (utility) of common complications of early cervical cancer treatment on quality of life (QOL). Utilities assigned by survivors were compared to those assigned by providers. METHODS:30 survivors of early cervical cancer identified from our Tumor Registry and 1...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2011.10.033

    authors: Einstein MH,Rash JK,Chappell RJ,Swietlik JM,Hollenberg JP,Connor JP

    更新日期:2012-04-01 00:00:00

  • Neuroendocrine carcinoma of the uterine cervix: the role of multimodality therapy in early-stage disease.

    abstract:BACKGROUND:Neuroendocrine carcinomas (NECs) of the cervix comprise only 2% of all cervical cancers. Prospective data is limited and treatment guidelines rely on retrospective reviews and literature from lung NEC. The objective of this study was to report our experience in the management of this rare disease. METHODS:T...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2013.01.014

    authors: McCann GA,Boutsicaris CE,Preston MM,Backes FJ,Eisenhauer EL,Fowler JM,Cohn DE,Copeland LJ,Salani R,O'Malley DM

    更新日期:2013-04-01 00:00:00

  • Lysophosphatidic acid (LPA) promotes E-cadherin ectodomain shedding and OVCA429 cell invasion in an uPA-dependent manner.

    abstract:OBJECTIVES:To evaluate the role of LPA in regulating E-cadherin cell surface expression, adhesion, and invasion in epithelial ovarian carcinoma (EOC) cells. METHODS:E-cadherin mRNA expression in OVCA429 and IOSE-29 cells was evaluated by real-time RT-PCR. Immunofluorescence and Western blot analysis were performed to ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2007.10.027

    authors: Gil OD,Lee C,Ariztia EV,Wang FQ,Smith PJ,Hope JM,Fishman DA

    更新日期:2008-02-01 00:00:00

  • Anatomic identification of nerve-sparing radical hysterectomy: a step-by-step procedure.

    abstract::The radical hysterectomy is often associated with severe bladder dysfunction and colorectal motility disorders. These issues may arise as a result of damage incurred to the motor and sensory autonomic nerve supply, both of sympathetic and parasympathetic origin, that innervate the uterus, vagina, urinary bladder, and ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2008.07.026

    authors: Fujii S

    更新日期:2008-11-01 00:00:00

  • Clear cell carcinoma of the ovary: a study of 59 cases.

    abstract::Clear cell carcinoma of the ovary accounts for 2 to 3% of all epithelial ovarian neoplasms. Patient profiles, pathological characteristics, and results of treatment are reviewed for 59 patients. The median age was 51. Disease extent at diagnosis was as follows: stage I, 18 patients (31%); stage II, 20 patients (34%); ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(89)90043-7

    authors: Crozier MA,Copeland LJ,Silva EG,Gershenson DM,Stringer CA

    更新日期:1989-11-01 00:00:00

  • Hormonal treatment of a recurrent granulosa cell tumor of the ovary: case report and review of the literature.

    abstract:BACKGROUND:Granulosa cell tumors of the ovary are rare, primarily treated surgically. In advanced or recurrent disease, data are inconclusive regarding the benefit of either primary or adjuvant chemotherapy. Hormonal therapy has been suggested as an alternative treatment. CASE:Our patient had three recurrences of estr...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.ygyno.2004.10.042

    authors: Hardy RD,Bell JG,Nicely CJ,Reid GC

    更新日期:2005-03-01 00:00:00

  • Type II endometrial cancer in Hispanic women: tumor characteristics, treatment and survival compared to non-Hispanic white women.

    abstract:OBJECTIVES:To compare survival of Hispanic white (HW) and non-Hispanic white (NHW) women with type II endometrial adenocarcinoma (EC). METHODS:Patients with serous, clear cell or grade 3 endometrioid EC were identified from the Surveillance, Epidemiology, and End Results (SEER) program 1988-2009 and were divided into ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2014.03.562

    authors: Mahdi H,Hou H,Kowk LL,Moslemi-Kebria M,Michener C

    更新日期:2014-06-01 00:00:00

  • Osteomalacia due to chemotherapy-induced Fanconi syndrome in an adult patient.

    abstract:BACKGROUND:Chemotherapy-induced Fanconi syndrome is a dangerous condition that could lead to severe electrolyte disturbances and rarely to osteomalacia. CASE:A patient treated with ifosfamide for a metastatic cervix squamous-cell carcinoma was admitted for diffuse, symmetric bilateral pain in bones and articulations. ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2005.05.014

    authors: Duck L,Devogelaer JP,Persu A,Berlière M,Caussin E,Baurain JF,Machiels JP

    更新日期:2005-08-01 00:00:00

  • The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice.

    abstract:OBJECTIVE:The opioid growth factor (OGF) and its receptor, OGFr, serve as a tonically active inhibitory axis regulating cell proliferation in normal cells and a variety of cancers, including human ovarian cancer. Blockade of OGF and OGFr with the nonselective opioid receptor antagonist naltrexone (NTX) upregulates expr...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2011.04.009

    authors: Donahue RN,McLaughlin PJ,Zagon IS

    更新日期:2011-08-01 00:00:00

  • CYP1A1, GSTM1, and GSTT1 polymorphisms and the risk of cervical squamous intraepithelial lesions in a multiethnic population.

    abstract:OBJECTIVE:In this investigation, we explored the hypothesis that genetic polymorphisms in the cytochrome P4501A1 (T3801C) and glutathione S-transferase classes mu and theta (GSTM1 and GSTT1) gene deletions promote the development of cervical dysplasia by moderating the activation and detoxification of polycyclic hydroc...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1006/gyno.2001.6154

    authors: Goodman MT,McDuffie K,Hernandez B,Bertram CC,Wilkens LR,Guo C,Seifried A,Killeen J,Le Marchand L

    更新日期:2001-05-01 00:00:00

  • Anastrozole therapy in recurrent ovarian adult granulosa cell tumors: a report of 2 cases.

    abstract:BACKGROUND:Ovarian sex cord stromal tumors are frequently hormonally active, and adult granulosa cell tumors often demonstrate estrogen receptor positivity. Thus, hormonal agents have been evaluated as potential treatments for advanced stage or recurrent adult granulosa cell tumors. CASE:Two cases of patients with rec...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2006.06.022

    authors: Freeman SA,Modesitt SC

    更新日期:2006-11-01 00:00:00

  • Necessity of routine cardiac evaluation in patients receiving pegylated liposomal doxorubicin for gynecologic cancer.

    abstract:OBJECTIVE:Pegylated liposomal doxorubicin (PLD) has similar reported clinical efficacy compared with conventional doxorubicin with less cardiotoxicity. The manufacturer of PLD advises that cardiac function should be evaluated with endomyocardial biopsy, echocardiography or multigated radionucleotide scan (MUGA) pre-tre...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2019.09.009

    authors: Dioun SM,Vilardo N,Goldberg GL,Gressel GM

    更新日期:2019-11-01 00:00:00

  • Role of PET or PET/CT in the post-therapy surveillance of uterine sarcoma.

    abstract:OBJECTIVE:To evaluate the clinical accuracy and clinical impact of positron emission tomography (PET) or positron emission tomography/computed tomography (PET/CT) in detecting and treating tumor recurrence in patients with treated uterine sarcoma. METHODS:Results of 36 patients who underwent PET or PET/CT in post-ther...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2008.01.030

    authors: Park JY,Kim EN,Kim DY,Suh DS,Kim JH,Kim YM,Kim YT,Nam JH

    更新日期:2008-05-01 00:00:00

  • Identification of inguinofemoral lymph node metastases by methylation markers in vulvar cancer.

    abstract:OBJECTIVE:Lymph node status in early-stage vulvar cancer can be accurately assessed by the sentinel-node (SN) procedure. Molecular techniques, such as DNA-methylation assay, might improve SN assessment. In this study, we selected methylation markers for vulvar cancer and determined if these methylation markers were sui...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2012.01.013

    authors: Oonk MH,Eijsink JJ,Volders HH,Hollema H,Wisman GB,Schuuring E,van der Zee AG

    更新日期:2012-05-01 00:00:00

  • Uterine leiomyosarcoma metastatic to the sphenoid sinus: a case report and review of the literature.

    abstract:BACKGROUND:Leiomyosarcoma (LMS) of the uterus is a rare neoplasm with an aggressive growth pattern. Although the majority of uterine LMS is diagnosed with disease confined to the uterus, the rate of recurrent disease is high. The most common sites of recurrent disease are lung, liver, and peritoneal cavity. The rate of...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.ygyno.2003.10.043

    authors: Sandruck J,Escobar P,Lurain J,Fishman D

    更新日期:2004-02-01 00:00:00

  • Prognostic value of pre-treatment human papilloma virus DNA status in cervical cancer.

    abstract:OBJECTIVE:Although the relationship between human papilloma virus (HPV) and cervical cancer is well established, the prognostic value of HPV status has not been determined, largely because previous studies have yielded conflicting results. This study aimed to investigate the prognostic value of pre-treatment HPV DNA fo...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2017.11.003

    authors: Chong GO,Lee YH,Han HS,Lee HJ,Park JY,Hong DG,Lee YS,Cho YL

    更新日期:2018-01-01 00:00:00

  • Trimetrexate in the treatment of recurrent or advanced leiomyosarcoma of the uterus: a phase II study of the Gynecologic Oncology Group.

    abstract:OBJECTIVE:This study was conducted to determine the objective response of trimetrexate in patients with advanced or recurrent leiomyosarcoma of the uterus. METHODS:Eligibility was restricted to patients with measurable disease who had received no more than one prior chemotherapy regimen, who had adequate bone marrow, ...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1006/gyno.2001.6482

    authors: Smith HO,Blessing JA,Vaccarello L

    更新日期:2002-01-01 00:00:00

  • Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer.

    abstract:OBJECTIVE:The AGO-OVAR16 study was designed to test the efficacy, safety, and tolerability of pazopanib maintenance after first-line chemotherapy in patients with newly diagnosed advanced ovarian cancer (AOC). METHODS:Nine hundred and forty patients with histologically confirmed AOC, International Federation of Gyneco...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.ygyno.2019.08.024

    authors: Vergote I,du Bois A,Floquet A,Rau J,Kim JW,Del Campo JM,Friedlander M,Pignata S,Fujiwara K,Colombo N,Mirza MR,Monk BJ,Tsibulak I,Calvert PM,Herzog TJ,Hanker LC,Meunier J,Lee JY,Bologna A,Carrasco-Alfonso MJ,Harter

    更新日期:2019-11-01 00:00:00

  • MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma.

    abstract:OBJECTIVE:The ABC transporter MRP2 (ABCC2) can mediate cisplatin efflux, and over-expression of MRP2 has been associated with cisplatin resistance in cancer cell lines. The aim of this study was to determine the role of MRP2 in modulating cisplatin cytotoxicity in normal cells as well as the relationship between MRP2 e...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2005.08.046

    authors: Guminski AD,Balleine RL,Chiew YE,Webster LR,Tapner M,Farrell GC,Harnett PR,Defazio A

    更新日期:2006-02-01 00:00:00

  • Travel distance, hospital volume and their association with ovarian cancer short- and long-term outcomes.

    abstract:OBJECTIVE:To examine patterns of patient travel among women with ovarian cancer and to explore the association between travel distance and short and long-term outcomes. METHODS:Women with stage II-IV epithelial ovarian cancer diagnosed from 2004 to 2016 who underwent primary surgery were identified in the National Can...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2020.05.017

    authors: Knisely A,Huang Y,Melamed A,Tergas AI,St Clair CM,Hou JY,Khoury-Collado F,Ananth CV,Neugut AI,Hershman DL,Wright JD

    更新日期:2020-08-01 00:00:00